Hepatology: Hepatology: Patients with hepatitis C-related hepatocellular carcinoma use interferon-free direct-action antiviral drugs to improve survival rates

Background and objectives:in Asia and Western countries, the survival data of patients with hepatitis C virus (HCV)-related hepatitis cell cancer (HCC) is limited after the use of interferon-free direct-action antiviral drugs (DAA) to achieve continuous virological response (SVR)Therefore, the study was designed to explore the survival rates of HCV-related HCC patients without HCV treatment and those who achieved SVRhow to:The researchers divided 1,676 patients withinfectionHCV-associated HCC into patients treated without HCV (untreated group) and SVR patients treated with DAA (SVR group) and matched through tendental score matching;Result:In this study, a total of 1,239 untreated patients and 437 SVR patients were included, and the total five-year survival rate of SVR patients was significantly higher after the start of HCV treatment (87.78%vs66.05%, P .001)Multivariate Cox regression shows that SVR is independently related to a 63% reduction in five-year total cause mortality (risk ratio of 0.37; 95% confidence interval : 0.16-0.83; P - 0.016) and 66 percentage reduction in liver-related mortality in 5 years after removal of liver transplant patients (HR, 0.34; 95% CI, 0.13-0.88; P-0.026) has a similar trendconclusions
Compared to patients who were not treated with HCV, the five-year survival rate of HCV-related HCC patients with SVR increased by 60%-70%Therefore, patients who qualify for HCC treatment should also consider DAA treatment